{
  "docId": "019dd923-622c-750b-8b97-5cb48bf2a635",
  "docSlug": "b8afd3741673",
  "documentTitle": "Chinook Therapeutics Inc (KDNY)",
  "authorId": "51_Muddy_Waters",
  "authorName": "Carson C. Block",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-05-16 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 18,
  "pageCount": 36,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses Kaplan-Meier survival curves to illustrate the effects of Atrasentan on primary composite renal outcomes in different patient cohorts.",
  "elementsJson": [
    "paragraph",
    "line_chart",
    "data_table",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b97-5cb48bf2a635/18",
  "deckHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635#slide-18",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Could the numerically increased deaths and heart failures, along with a statistically-significant increase in anemia and hypervolemia, account for the abrupt end to the SONAR trial? And if so, why would Chinook in-license a drug this hazardous?",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-25b7-709e-b8d0-cc29cd7de9a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.604,
        "w": 0.334,
        "x": 0.333,
        "y": 0.188
      },
      "kind": "chart",
      "text": "Figure 4: Effects of atrasentan on the primary composite renal outcome in non-responders and all responders and non-responders combined",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "06097494-9366-4310-96aa-c6e080b9bdea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Hazard ratio: 0.75",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-25b7-709e-b8d0-d267df412c65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.061,
        "w": 0.763,
        "x": 0.118,
        "y": 0.093
      },
      "kind": "paragraph",
      "text": "It seems therefore that the similar (almost identical) mortality numbers, along with a lack of the desired “response” to atrasentan in the enrichment period, suggest a direct relationship between the mechanism of “response” and the mechanism of mortality.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "107caf3f-7440-48f5-8b22-2e55e07f56c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.763,
        "x": 0.118,
        "y": 0.73
      },
      "kind": "paragraph",
      "text": "Drugs with similar mechanisms to that of atrasentan have been shown in the past to increase the odds of heart failure. One indicator the authors report shows an increasing stress on patients’ cardiovascular systems—brain natriuretic peptide, or BNP.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c02eefc-8d02-4ade-af5b-c5f9c9ec818f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.763,
        "x": 0.118,
        "y": 0.655
      },
      "kind": "paragraph",
      "text": "Could the numerically increased deaths and heart failures, along with a statistically-significant increase in anemia and hypervolemia, account for the abrupt end to the SONAR trial? And if so, why would Chinook in-license a drug this hazardous?",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb7a8271-803c-4fe7-9ea6-88853a674afb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.118,
        "y": 0.865
      },
      "kind": "source-note",
      "text": "95, 96, 97: Citations for SONAR trial and cardiovascular stress indicators.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86c82ea4-8deb-44a3-8e1c-653a6d4e8497",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.18,
        "x": 0.118,
        "y": 0.7
      },
      "kind": "title",
      "text": "Mechanism of Hazard",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4095b348-3e4f-4835-b493-0e1834a97d6b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Analytical method",
      "slug": "analytical-method",
      "agent": null,
      "layer": "slide",
      "matchId": "a362b008-69c6-4c26-98b2-4faa078de8be",
      "evidence": "The slide mentions a 'mechanism of hazard' and discusses the relationship between atrasentan and increased odds of heart failure.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}